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Introduction
Cardiogenic shock independently of its etiology remains a
clinical challenge and its mortality remains unacceptably
high. Extracorporeal life support (ECLS) devices provide
temporary mechanical circulatory support in patients on
refractory cardiogenic shock and are usually implanted
under emergency conditions in critical patients.
Objectives
To assess etiology, indication and outcome of patients
supported with veno-arterial extracorporeal membrane
oxygenation (VA-ECMO).
Methods
Retrospective observational study collecting all patients
who were supported with VA-ECMO at our institution
from June 2010 to March 2015. Patients who were
placed on ECMO post-cardiotomy were excluded.
Results
During the study period fifty-five patients were supported
with VA-ECMO with mean age of 42 (16-66), being male
75%. The aetiology of cardiogenic shock was acute ischae-
mic heart disease (IHD) 10 patients (18,18%), chronic IHD
with decompensated heart failure (DHF) 9 patients
(16,36%), dilated cardiomyopathy with DHF 24 patients
(43,63%), acute heart failure secondary to miocarditis
8 patients (14,54%) or other (pheochromocytoma, cardiac
sarcoma, peripartum) 4 patients (7,27%).
Our approach to cannulation was mainly peripheral,
52 patients (94,54%). 19 patients were supported with
combined IABP (35,54%), with higher incidence in the
ischaemic heart disease group. Average duration of
ECMO support was 7,2 days+/- 4,8 days (range: 1-20).
ECMO weaning was possible in 30 patients (54,54%).
Total recovery of heart function at hospital discharge
was observed in 12 patients (21,81%).
16 of our patients were upgraded to long term support
(Heartware HVAD® System) as a bridge to transplant.
During the study period 4 patients received a heart
transplant.
ITU mortality was 27,27% (15 patients) and overall
mortality at hospital discharge was 43,63%
(24 patients). Refractory shock with multi-organ fail-
ure was the most common cause of death
(16 patients, 29%), followed by complications related
with ECMO, as uncontrolled haemorrhage
(12,72%, 7 patients).
Cardiogenic shock secondary to myocarditis represents
the group with better overall survival, 100%, and IHD
the one with higher mortality rate.
Conclusions
VA-ECMO can be indicated in patients with refractory
cardiogenic shock who have an underlying potentially
reversible heart condition, although it can also be used as
a bridge to a ventricular assist device or cardiac trans-
plantation In-hospital survival rate of patients with VA-
ECMO varies up to 50% according to the cause of the
cardiac dysfunction. It remains difficult to determine
which patients will benefit from VA-ECMO and when
this support will be futile. Patients who require ECMO as
a result of reversible causes such as myocarditis appear
to have the best prognosis with higher rate of recovery.
Outcome remains worst for patients with cardiogenic
shock related with IHD.Royal Brompton and Harefield Trust, London, United Kingdom
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